You are here

  • Home
  • Archive
  • Volume 75, Issue 2
  • IL-6-driven STAT signalling in circulating CD4+ lymphocytes is a marker for early anticitrullinated peptide antibody-negative rheumatoid arthritis

Article info

Article menu
Basic and translational research
Extended report
IL-6-driven STAT signalling in circulating CD4+ lymphocytes is a marker for early anticitrullinated peptide antibody-negative rheumatoid arthritis

Authors

  • Amy E Anderson National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle upon Tyne, UK PubMed articlesGoogle scholar articles
  • Arthur G Pratt National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle upon Tyne, UK PubMed articlesGoogle scholar articles
  • Mamdouh A K Sedhom The University of Queensland Diamantina Institute, Translational Research Institute, Woolloongabba, Queensland, Australia PubMed articlesGoogle scholar articles
  • John Paul Doran National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle upon Tyne, UK PubMed articlesGoogle scholar articles
  • Christine Routledge National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle upon Tyne, UK PubMed articlesGoogle scholar articles
  • Ben Hargreaves National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle upon Tyne, UK PubMed articlesGoogle scholar articles
  • Philip M Brown National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle upon Tyne, UK PubMed articlesGoogle scholar articles
  • Kim-Anh Lê Cao The University of Queensland Diamantina Institute, Translational Research Institute, Woolloongabba, Queensland, Australia PubMed articlesGoogle scholar articles
  • John D Isaacs National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle upon Tyne, UK PubMed articlesGoogle scholar articles
  • Ranjeny Thomas The University of Queensland Diamantina Institute, Translational Research Institute, Woolloongabba, Queensland, Australia PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Arthur G Pratt, Institute of Cellular Medicine (Musculoskeletal Research Group), Newcastle University, Newcastle upon Tyne NE2 4HH, UK; arthur.pratt{at}ncl.ac.uk
View Full Text

Citation

Anderson AE, Pratt AG, Sedhom MAK, et al
IL-6-driven STAT signalling in circulating CD4+ lymphocytes is a marker for early anticitrullinated peptide antibody-negative rheumatoid arthritis
Annals of the Rheumatic Diseases 2016;75:466-473.

Publication history

  • Received May 2, 2014
  • Revised December 10, 2014
  • Accepted December 15, 2014
  • First published February 3, 2015.
Online issue publication 
October 25, 2017

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/